Two types of oral antiviral drugs have been prescribed to COVID-19 patients since the fifth wave of the pandemic in Hong Kong. The Jockey Club School of Public Health and Primary Care at CU Medicine and the Department of Emergency Medicine at HKUMed conducted a retrospective cohort analysis between February and March 2022, also known as the peak of the fifth wave, involving 54,355 COVID-19 outpatients in designated clinics and inpatients in public hospitals in Hong Kong. The research included patients who were 60 years old or above, and patients under the age of 60 with at least one chronic disease. Among these patients, 20% were prescribed either one of the oral drugs.
The study revealed that the oral antiviral agent strategy may reduce the risk of death in hospitalised patients by 76%. The risk of hospital admission in outpatients was also reduced by 88%. Nirmatrelvir-Ritonavir (Pfizer’s oral drug) may save over HK$43,000 by preventing one death when compared to usual methods of care.
The study findings have just been published in The Lancet Regional Health – Western Pacific.
Dr Crystal Chan Ying, co-first author of the study and Postdoctoral Fellow from The Jockey Club School of Public Health and Primary Care at CU Medicine, said, “In COVID-19 patients with mild symptoms, both Molnupiravir and Nirmatrelvir-Ritonavir prescriptions were associated with reduced all-cause mortality and healthcare utilisation, while Nirmatrelvir-Ritonavir was associated with significant cost savings in inpatient settings.”
Professor Eliza Wong Lai-yi, co-corresponding author of the study from The Jockey Club School of Public Health and Primary Care at CU Medicine, commented, “To ensure the sustainability of the healthcare system, it is recommended that a triage mechanism should be in place to refer COVID-19 patients with mild to moderate symptoms to designated clinics or collaborating general practitioners for timely prescription of oral antiviral agents.”
Details: Faculty of Medicine, CUHK: https://bit.ly/3EiIphv
Full article of the study: https://bit.ly/3CgCW8y
大公報 - 新冠口服药可降76%死亡风险
明報 - 研究：用輝瑞口服藥 治住院者省4萬
文匯報 - 研究揭口服藥降死亡風險近八成
HKET Topick -【新冠口服藥】大學研究指服藥後死亡風險降逾7成 每使用輝瑞藥可降約4.3萬醫療成本
香港商報 - 中大港大研究發現新冠口服藥可降低住院患者死亡風險近8成
香港電台 - 研究指服用新冠口服藥住院病人較沒服藥死亡率降76%
新城電台 - 研究:新冠口服藥可降住院患者死亡風險近8成
晴報 - 增3642人染疫 入境客個案數字穩定
香港電台 - 中大指新冠口服藥可降死亡率 醫療系統亦能承擔成本